Screening for hepatitis B

Extract

1 Translation of the key statement of the final report S16-03 Screening auf Hepatitis B (Version 1.0; Status: 19 September 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding.
Publishing details

Publisher:
Institute for Quality and Efficiency in Health Care

Topic:
Screening for hepatitis B

Commissioning agency:
Federal Joint Committee

Commission awarded on:
22 September 2016

Internal Commission No.:
S16-03

Address of publisher:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Im Mediapark 8
50670 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
E-mail: berichte@iqwig.de
Internet: www.iqwig.de
This report was prepared in collaboration with external experts.

The responsibility for the contents of the report lies solely with IQWiG.

According to §139b (3) No. 2 of Social Code Book (SGB) V, Statutory Health Insurance, external experts who are involved in the Institute’s research commissions must disclose “all connections to interest groups and contract organizations, particularly in the pharmaceutical and medical devices industries, including details on the type and amount of any remuneration received”. The Institute received the completed Form for disclosure of potential conflicts of interest from each external expert. The information provided was reviewed by a Committee of the Institute specifically established to assess conflicts of interests. The information on conflicts of interest provided by the external experts and external reviewers is presented in Chapter A9 of the full report. No conflicts of interest were detected that could endanger professional independence with regard to the work on the present commission.

**External experts**
- Tim Mathes, Institute for Research in Operative Medicine, University Witten/Herdecke, Cologne, Germany
- Dawid Pieper, Institute for Research in Operative Medicine, University Witten/Herdecke, Cologne, Germany

IQWiG thanks the external experts for their collaboration in the project.

**IQWiG employees**
- Sandra Molnar
- Oliver Assall
- Daniel Fleer
- Ulrike Lampert
- Lina Rodenhäuser
- Stefan Sauerland
- Wiebke Sieben
- Siw Waffenschmidt

**Keywords:** Mass Screening, Hepatitis B, Benefit Assessment, Systematic Review
Key statement

Research question

The aim of this report is to assess the benefit of hepatitis B virus (HBV) screening compared to no screening with regard to patient-relevant outcomes in asymptomatic patients. At-risk groups, which already undergo regular testing for HBV infection according to current medical standards in Germany (such as healthcare workers), are not the primary focus of this report.

Conclusion

No comparative interventional studies of the screening chain or therapy studies on earlier treatment initiation were found. Since it was not possible to show a benefit of the earlier initiation of HBV treatment, the diagnostic quality of HBV screening was not assessed.

An examination of the arguments and evidence found in international guidelines on the benefit and harm of HBV screening shows that these screening recommendations for at-risk groups were made without sufficient evidence and were not based on reasonable assumptions. In the absence of robust evidence, the benefit-to-harm ratio for HBV screening remains unclear overall.

Given the availability of a vaccine against HBV, the topic of HBV screening will become less relevant over time since the percentage of the population which might benefit from screening will continue to decrease.

The full report (German version) is published under https://www.iqwig.de/de/projekte-ergebnisse/projekte/nichtmedikamentoesen-verfahren/s-projekte/s16-03-screening-auf-hepatitis-b.7583.html